Section of Microbiology, Division of
Biological Sciences, University of California at Davis, Davis,
California 95616
Received 22 January 1998/Returned for modification 10 March
1998/Accepted 11 June 1998
A variety of eukaryotic transcription factors, including the
nuclear hormone receptors, Max-Mad, BCL-6, and PLZF, appear to mediate
transcriptional repression through the ability to recruit a
multiprotein corepressor complex to the target promoter. This corepressor complex includes the SMRT/N-CoR polypeptides,
mSin3A or -B, and histone deacetylase 1 or 2. The presence of a
histone-modifying activity in the corepressor complex has led to the
suggestion that gene silencing is mediated by modification of the
chromatin template, perhaps rendering it less accessible to the
transcriptional machinery. We report here, however, that the
corepressor complex actually appears to exhibit multiple mechanisms of
transcriptional repression, only one of which corresponds with
detectable recruitment of the histone deacetylase. We provide evidence
instead of an alternative pathway of repression that may be mediated by
direct physical interactions between components of the corepressor
complex and the general transcription factor TFIIB.
 |
INTRODUCTION |
Many transcription factors can exert
both positive and negative effects on gene expression. The Ying-Yang-1
(YY-1) transcription factor, for example, can either repress
or activate transcription at different promoters, whereas the Max
transcription factor alternatively heterodimerizes with either a
transcriptional activator (Myc) or a transcriptional repressor (Mad) to
yield bimodal regulation of a given target gene (2, 16, 41, 49,
52, 57). Similarly, certain nuclear hormone receptors, such as
thyroid hormone receptors (T3Rs), are capable of the alternative
repression or activation of target gene expression, depending on
hormone status, the constitution of the target promoter, and the
cellular environment (4, 6-8, 12, 40). These dual
regulatory properties arise, in part, from the ability of these
transcription factors to physically recruit auxiliary
polypeptides that help mediate the actual transcriptional response. T3Rs, for example, typically function as transcriptional silencers in the absence of hormone, a context in which these receptors
bind to a class of corepressor proteins denoted SMRT/ N-CoR (SMRT
and N-CoR, also known as TRAC and RIP13, are interrelated proteins
produced by two distinct genetic loci) (10, 11, 15, 24, 26, 29,
31, 39, 42-44, 54-56, 58). Addition of hormone converts T3Rs
into strong transcriptional activators, a process that is accompanied
by the release of the SMRT/N-CoR corepressor polypeptides and
the physical association of the receptors with a new set of proteins
that function as transcriptional coactivators (10, 11, 24, 26,
29, 31, 39, 42-44, 54-56, 58; for a review, see reference
25).
Significant progress in understanding the role of SMRT/N-CoR proteins
in transcriptional silencing has recently been made. The
SMRT/N-CoR proteins can associate with other polypeptides to form a large corepressor complex containing mSin3A or -B, histone deacetylase-1 (HDAC-1) or HDAC-2, retinoblastoma
protein-associated protein 46 (RbAp-46) or RbAp48, and at least two
other polypeptides of unknown function (denoted SAP18 and -30, for silencer-associated proteins) (1, 3, 21, 22, 30, 31,
59; for reviews, see references 37 and
51). Although SMRT and N-CoR were initially identified as corepressors for the nuclear hormone receptors, the
components of the SMRT/N-CoR-Sin3-HDAC complex can interact with,
and appear to play a key role in transcriptional silencing by, a wide
variety of nonreceptor transcription factors, including Mad-Max, YY-1,
PLZF, BCL-6, and the retinoblastoma gene product (1, 3, 14,
21-23, 30, 31, 52, 59); orthologs of this complex have
also been implicated in gene silencing in yeast (28, 34, 36, 45,
46, 48). Notably, different transcription factors can recruit the
corepressor complex by interacting with different components of the
complex: the nuclear hormone receptors appear to contact
primarily the SMRT/N-CoR component, Mad-Max interacts
principally with mSin3, and PLZF makes a combination of contacts
with SMRT/N-CoR, mSin3, and HDAC (1, 10, 14, 19, 23, 24, 30,
32, 39, 42, 51a, 56).
Once tethered to a target promoter through interaction with a specific
transcription factor, how does the SMRT corepressor complex
actually silence transcription? The presence of HDAC-1 or -2 in the corepressor complex has led to the suggestion that transcription
repression may reflect a deacetylation of the adjacent chromatin
template (reviewed in references 37 and
51). This hypothesis provides a conceptual symmetry
to the observation that many transcriptional coactivators possess
reciprocal histone acetyltransferase activities and is consistent with
the proposal that histone acetylation enhances, whereas
deacetylation restricts, the accessibility of chromatin to the
general transcriptional machinery (16, 49). However,
chromatin remodeling is unlikely to be the sole mechanism of
SMRT corepressor-mediated transcriptional silencing. For example, nuclear hormone receptors repress transcription in contexts (such as transient transfections and transcription assays in vitro) where the bulk of the DNA templates are not fully assembled into chromatin (see, e.g., references 5, 8, 12, 18, and
40). Furthermore, inhibition of HDAC
activity in yeast, Drosophila, and vertebrate cells produces
complex, mixed phenotypes involving both loss of repression and loss of
activation (13, 27, 35, 38, 46, 47).
To better elucidate the mechanism(s) of repression, we sought to
further dissect the nature and function of the SMRT-mSin3 corepressor
complex. We report here that silencing by the corepressor complex
appears to utilize multiple mechanisms of transcriptional repression,
only one of which corresponds with recruitment of the HDAC. We also
provide evidence of an alternative pathway of repression that may be
mediated by direct physical interactions between components of the
corepressor complex and the general transcription factor TFIIB.
 |
MATERIALS AND METHODS |
In vitro protein-protein binding assays.
The construction of
the glutathione S-transferase (GST)-SMRT fusions was
previously described (23, 39). Similar GST fusion constructs, representing various portions of the mSin3A-coding region,
were constructed by cleavage of the pGEX-KG vector (20) and
the target DNA at appropriate restriction sites and ligation by
standard recombinant DNA methodology. The GST fusion proteins were
expressed in Escherichia coli DH5
and were purified and immobilized to glutathione-agarose as previously described
(20).
35S-radiolabeled mSin3A, TFIIB, or HDAC-1 was
synthesized in vitro by use of the appropriate pSG5-, pT7
-, or
pVZ-based plasmid in a coupled transcription-translation system (TnT
kit; Promega). The 35S-labeled proteins were then incubated
with a 50% slurry of the corresponding immobilized GST fusion protein
in 200 to 300 µl of HEMG binding buffer (40 mM HEPES [pH 7.8],
50 mM KCl, 0.2 mM EDTA, 5 mM MgCl2, 0.1% Triton
X-100, 10% glycerol, 1.5 mM dithiothreitol, 1× Complete Protease
Inhibitor [Boehringer-Mannheim], and 0.5 mg of bovine serum albumin
per ml) for 1 h at 4°C with gentle rocking. The agarose beads
were then washed four times with 1 ml (each time) of HEMG buffer in the
absence of protease inhibitor and bovine serum albumin. Bound
proteins were eluted in 30 µl of 50 mM Tris-Cl (pH 6.8) containing
100 mM glutathione, resolved by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and
visualized and quantified by PhosphorImager analysis (Molecular Dynamics Storm System) (23, 39).
Mammalian repression and two-hybrid assays.
The
HindIII fragment of pACT2 (Clontech) was inserted
between linker-modified EcoRI and BamHI
sites of pSG5 (Stratagene) to create the pSG5-GAL4AD vector. The
pSG5-GAL4DBD vector was created by transferring the
HindIII-to BamHI portion of pGBT9 (Clontech) as a blunt-end fragment into the similarly treated EcoRI and
BamHI sites of pSG5. The pSG5-GAL4DBD and pSG5-GAL4AD open
reading frames in these pSG5 vectors were subsequently fused in frame
to various subdomains of SMRT, mSin3A, or TFIIB by use of appropriate
restriction sites and standard recombinant DNA subcloning techniques.
Transient transfections of CV-1 cells were performed by a calcium
phosphate coprecipitation method (23). Each 60-mm-diameter plate, representing approximately 2.5 × 105 cells,
was transfected with 500 ng of a pGAL-(17mer)-simian virus 40 (SV40)
late promoter-luciferase reporter (23), 125 ng of the
pSG5-GAL4DBD vector, 500 ng of the pSG5-GAL4AD vector, 500 ng of a
pCH110 vector (Pharmacia) as an internal
-galactosidase control, and
sufficient pUC19 to normalize the total DNA to 5 µg. Luciferase
activity was determined after 46 h with a luciferase assay kit
(Promega) and a TD 20/20 luminometer (Turner Design). The relative
light units were normalized to the
-galactosidase activity.
 |
RESULTS |
The SMRT polypeptide possesses at least two distinct
silencing domains that repress transcription when tethered to DNA, and
one of these silencing domains strongly interacts with mSin3A in vivo
and in vitro.
Prior work has indicated that the C-terminal
half of SMRT serves to tether this protein to the nuclear hormone
receptors, whereas the N-terminal half encompasses the domains that
actually mediate transcriptional repression (see, e.g., references
10, 11, 24, 39, 42, and 54) (Fig.
1A). Our first goal was to more precisely
determine the locations of these N-terminal silencing domains within
SMRT. We therefore fused different segments of SMRT to an exogenous
GAL4 DNA binding domain (GAL4-DBD) and then tested the ability of these
fusion proteins to inhibit the expression of a promoter containing GAL4
binding sites linked to a suitable luciferase reporter gene. The
constructs and reporter were introduced into CV-1 cells, and the
luciferase activity relative to that of a
-galactosidase reporter
introduced as an internal control was determined (Fig. 1B). Two
separate and strong repression domains could be mapped in SMRT by this
means: silencing domain 1 (SD-1), encompassing amino acids 214 to 474, and SD-2, encompassing amino acids 566 to 680 (Fig. 1B). These two
domains represented the preponderance of the silencing activity of SMRT
detectable in this fashion; constructs limited to the C-terminal
half of SMRT exhibited little or no repression as determined by this
form of assay (Fig. 1B) and in fact functioned as dominant
negative inhibitors of native SMRT function.

View larger version (19K):
[in this window]
[in a new window]
|
FIG. 1.
Transcriptional silencing domains in SMRT. (A) Schematic
representation of the SMRT corepressor. The regions involved in
interactions with the nuclear hormone receptors are indicated (denoted
receptor interaction domains, RID-1 and RID-2), as are the regions able
to mediate transcriptional repression when expressed as GAL4-DBD
fusions (SD-1 and SD-2). Numbers above the schematic refer to the
relevant amino acid positions. (B) Domains of SMRT able to repress
reporter gene expression in a transient-transfection assay. Different
regions of SMRT, as depicted schematically on the left, were fused in
frame to a GAL4-DBD-coding sequence and were expressed in CV-1
mammalian cells. The cells were simultaneously transfected with a
reporter plasmid containing an SV40 late promoter bearing five binding
sites (GAL4 17-mers) for the GAL4-DBD and driving the expression of a
luciferase reporter gene. The cells were harvested 48 h later, and
the luciferase activity was determined relative to that of a pCH110
-galactosidase reporter, lacking GAL4 binding sites, employed as a
negative control. Fold repression (right) was calculated as the
reduction in luciferase expression mediated by a GAL4-DBD fusion
construct relative to that mediated by an empty GAL4-DBD (DBD). The
results presented represent the averages and standard deviations
obtained from at least two duplicate experiments.
|
|
It has been suggested that SMRT-mediated repression requires the
association of this protein with mSin3 (3, 22). We
therefore sought to map the sites of interaction between SMRT
and mSin3. We first tested the ability of radiolabeled mSin3A,
synthesized by in vitro transcription-translation, to bind to a panel
of different SMRT domains, expressed as GST fusions in E. coli and immobilized on a glutathione-agarose matrix (Fig.
2). Consistent with the hypothesis, the
SD-1 of SMRT (amino acids 214 to 474) contains a strong binding site
for mSin3 as determined by this in vitro assay, whereas mSin3A
exhibited little or no binding to nonrecombinant GST or to sequences
derived from the C-terminal half of SMRT (Fig. 2). A mammalian
two-hybrid assay confirmed that these interactions also occurred in an
in vivo context: GAL4 activation domain (AD) fusions containing the
SMRT SD-1 displayed a strong functional interaction with an assortment
of GAL4-DBD-mSin3A constructs when the two were coexpressed in CV-1
cells (Fig. 3C) (discussed in greater
detail below). In contrast, regions of SMRT that lacked the SD-1 failed
to detectably interact with mSin3A in the two-hybrid assay (Fig. 3C).
Truncation of the SMRT SD-1 to amino acids 214 to 336 significantly
impaired the ability to associate with mSin3 both in vitro and in vivo
(Fig. 2 and 3C) and the ability of SD-1 to repress transcription (Fig.
1B), indicative of a correlation between these two functions.
Intriguingly, however, we were unable to demonstrate an equivalent
interaction between mSin3A and the SMRT SD-2 region (amino acids 566 to
680) (Fig. 2 and data not shown) despite the strong repression
phenotype exhibited by the latter (Fig. 1B).

View larger version (32K):
[in this window]
[in a new window]
|
FIG. 2.
Localization of an interaction site for mSin3A within
the SMRT polypeptide. Full-length, radiolabeled mSin3A was
synthesized in vitro by a coupled transcription-translation
protocol. The radiolabeled mSin3A protein was then incubated with
various domains of SMRT, expressed in bacteria as GST fusion proteins,
and immobilized on a glutathione-agarose column (the SMRT amino acids
represented in each GST fusion are denoted above the panels; GST refers
to a nonrecombinant GST construct employed as a negative control). The
radiolabeled mSin3A protein bound by each GST-SMRT construct was eluted
with soluble glutathione, resolved by SDS-PAGE, and visualized and
quantified by PhosphorImager analysis. The percentage of the input
mSin3A bound by each GST fusion is indicated below each lane.
|
|

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 3.
Comparative mapping of repression and SMRT interaction
domains located within mSin3A. (A) Schematic representation of mSin3A.
The locations of four putative paired amphipathic helical domains, PAH1
through -4, are shown. Also depicted are the locations of two domains
within mSin3A (SD-A and SD-B) that are able to repress transcription
when expressed as GAL4-DBD fusions and the locations of two domains
within mSin3A that are able to interact with SMRT. Numbers above the
schematic refer to the relevant amino acid positions. (B) Domains of
Sin3A able to repress transcription in a transient-transfection assay.
Different domains of mSin3A, as depicted schematically on the left,
were fused to a GAL4-DBD-coding frame and expressed in CV-1 mammalian
cells. The cells were simultaneously transfected with a reporter
plasmid containing an SV40 late promoter bearing five binding sites
(GAL4 17-mers) for the GAL4-DBD and driving the expression of a
luciferase reporter gene. The cells were harvested 48 h later, and
the luciferase activity was determined relative to that of a pCH110
-galactosidase reporter, lacking GAL4 binding sites, employed as an
internal control. Fold repression (right) was calculated as the
reduction in luciferase expression mediated by a GAL4-DBD fusion
construct relative to that mediated by an empty GAL4-DBD (DBD). The
results represent the averages and standard deviations from at least
two duplicate experiments. (C) Domains of mSin3A able to interact with
SMRT in a mammalian two-hybrid interaction. GAL4-DBD fusions
representing different domains of mSin3A, as depicted schematically on
the left of the panel, were introduced into CV-1 cells together with
the GAL4 (17-mer) luciferase reporter and a series of GAL4-AD
constructs. The GAL4-AD constructs included an empty GAL-AD construct,
a GAL4-AD-SMRT (codons 96 to 566) construct, a GAL4-AD-SMRT (codons
751 to 1495) construct, a GAL4-AD-SMRT (codons 214 to 474) construct,
and a GAL4-AD-SMRT (codons 214 to 336) construct. After 48 h, the
cells were harvested and the luciferase activity was determined
relative to that of pCH110 employed as an internal control (Relative
Luc). The results represent the averages and standard deviations from
at least two duplicate experiments.
|
|
The mSin3A polypeptide itself contains two autonomous
transcriptional silencing domains, only one of which detectably
interacts with HDAC-1.
The mSin3A molecule is comprised of
four repetitive domains believed to represent paired amphipathic
helices (PAH1 through -4), separated by regions of unique sequence
(50) (Fig. 3A). We therefore employed the GAL4-DBD
fusion technique to map the regions within this mSin3A structure
capable of transcriptional repression. Two distinct mSin3A domains
possessed strong silencing activity when assayed in this manner: mSin3A
amino acids 57 to 215 (denoted SD-A and encompassing PAH-1 and a region
of N-terminal flanking sequence) and amino acids 533 to 724 (denoted SD-B and located between PAH3 and PAH4) (Fig. 3B). In
contrast, PAH2, PAH3, and PAH4 of mSin3A exhibited little or no
silencing activity when tested in the same fashion (Fig. 3B).
We next mapped the regions of mSin3A responsible for its interaction
with SMRT, using the mammalian two-hybrid assay (Fig. 3C). Two SMRT
interaction domains were detected within mSin3A: the first
coincided with PAH2 (mSin3 amino acids 272 to 404), and the second
included PAH3 (mSin3 amino acids 404 to 545) (Fig. 3C). Significantly,
the two SMRT association domains within mSin3A were fully separable
from the two mSin3 silencing domains, strongly implying that mSin3A
does not require a direct interaction with SMRT for transcription
repression when tethered directly to a promoter as a GAL4-DBD
fusion.
The ability of mSin3 to silence transcription has been proposed to be
linked to its ability to recruit HDAC-1 and -2 and to thereby
remodel chromatin into a transcriptionally nonpermissive structure
(reviewed in references 37 and
51). Using an in vitro binding assay, we first
confirmed and extended prior results that were obtained more
indirectly (1, 3, 21, 22, 30, 59), namely, that
HDAC-1 can bind to mSin3A (Fig. 4A).
This HDAC-1 association site mapped to amino acids 545 to
1157 of mSin3A (Fig. 4B) and thus includes the SD-B of mSin3A,
consistent with the concept that SD-B-mediated repression might operate
through recruitment of the HDAC moiety. In contrast, however, the
second, strong repression domain SD-A, located at the N terminus of
mSin3A, exhibited no detectable interaction with HDAC-1
(compare Fig. 3B and 4A). These results suggest that both
HDAC-1-dependent and -independent mechanisms of transcriptional
repression may be operative in mSin3A. Consistent with the work of
others, we did not observe any evidence of a direct interaction between
HDAC-1 and any region of SMRT (data not shown).

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 4.
Interaction of HDAC-1 with mSin3A and effects of
trichostatin A on repression. (A) Binding of mSin3A to GST-HDAC-1.
Full-length, radiolabeled mSin3A was synthesized in vitro by a coupled
transcription-translation protocol. The radiolabeled mSin3A protein was
then incubated with nonrecombinant GST (used as a negative control) or
a GST fusion of HDAC-1, each expressed in bacteria and immobilized
on a glutathione column. Radiolabeled mSin3A protein bound to the
immobilized proteins was eluted with soluble glutathione, resolved by
SDS-PAGE, and visualized and quantified by PhosphorImager analysis
(left panel). The percentage of HDAC-1 bound to GST or to
GST-HDAC-1 is depicted below the panel and was determined relative
to the total radiolabeled mSin3A used in the assay (input). A parallel
experiment using radiolabeled PLZF as a positive control for
interaction with HDAC-1 is also presented (right panel). (B)
Binding of HDAC-1 to GST-mSin3A. An experiment reciprocal to that
in panel A was performed, using radiolabeled, full-length HDAC-1
and GST fusions representing various portions of mSin3A (as indicated
above the lanes). Radiolabeled HDAC-1 protein bound to the
different GST-mSin3A fusion constructs was eluted, resolved by
SDS-PAGE, and visualized and quantified by PhosphorImager analysis, as
described for panel A. (C) Lack of effect of trichostatin A on
SMRT-mSin3A-mediated transcriptional repression. Various GAL4-DBD
fusions representing the silencing domains of SMRT and mSin3A, as
indicated below each panel, were transfected into CV-1 cells together
with an SV40 late promoter (GAL4 17-mer) luciferase reporter in the
presence or absence of 10 nM trichostatin A (TSA), an inhibitor of HDAC
activity. The cells were harvested 48 h later, and the expression
of the luciferase reporter, relative to that of the pCH100 internal
control, was determined ("Relative Luc"). The results presented
represent the averages and standard deviations obtained from at least
two duplicate experiments.
|
|
As a different means of evaluating the role of histone modification in
mSin3A-mediated gene silencing, we also tested the ability of a strong
inhibitor of HDAC, trichostatin A, to counteract mSin3A-mediated
repression (53). Levels of trichostatin A ranging up to
near-toxic concentrations had no detectable effect on repression in our
assays when tested with any of the silencing domains we elucided in our
GAL4-DBD-mSin3A or GAL4-DBD-SMRT constructs (Fig. 4B). We conclude
that HDAC activity is not a necessary prerequisite for mSin3A- or
SMRT-mediated gene silencing in the transient-transfection assays
described here.
General transcription factor TFIIB strongly interacts with
components of the SMRT corepressor complex and may be a target for
corepressor-mediated gene silencing.
Our studies described above
indicated that gene silencing by corepressor includes mechanisms
operating in addition to, or in conjunction with, the previously
recognized ability of the SMRT-mSin3A complex to tether
HDAC-1. Notably, many transcription factors, including the nuclear
hormone receptors, interact directly with components of the general
transcriptional machinery, and these interactions have been proposed to
be an important mechanism of transcriptional regulation (see, e.g.,
reference 9 and references therein). Highly purified
T3R, for example, is able to mediate transcriptional repression in
vitro in the absence of detectable coregulators, apparently through
direct inhibitory interactions between receptor and TFIIB and/or
TFIID (5, 17, 18). We therefore investigated whether the
SMRT corepressor might contribute to transcriptional silencing by also
targeting components of the general transcriptional machinery, perhaps
in synergy with the known inhibitory interactions between T3R and the
preinitiation complex.
Indeed, we observed that SMRT strongly interacted with general
transcription factor TFIIB in vitro (Fig.
5A). The interactions between SMRT and
TFIIB were quite marked, being comparable to in strength or stronger
than those observed between SMRT and T3R, and could also be observed in
a reciprocal experiment using radiolabeled SMRT derivatives and a
GST-TFIIB fusion polypeptide (data not shown). In contrast,
little or no TFIIB bound to a nonrecombinant GST construct or to an
assortment of other GST fusions employed as negative controls (Fig. 5A
and data not shown).

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 5.
Interactions of TFIIB with SMRT. (A) Binding in
vitro. Radiolabeled TFIIB was synthesized in vitro by a coupled
transcription-translation protocol (input lane; the presence of a
protein doublet is likely the result of translational initiations on
both the correct codon and an internal AUG codon). The radiolabeled
TFIIB protein was then incubated with various domains of SMRT (as
denoted above the lanes), each expressed in bacteria as a GST fusion
protein and immobilized on a glutathione-agarose column. Radiolabeled
TFIIB bound to the different GST-SMRT agarose matrices was eluted with
soluble glutathione, resolved by SDS-PAGE, and visualized and
quantified by PhosphorImager analysis. The binding of TFIIB to
nonrecombinant GST (GST) was also tested in parallel as a negative
control. The percentage of the input TFIIB bound by each GST fusion is
depicted below each lane. (B) Two-hybrid interaction between SMRT and
TFIIB. Various subdomains of SMRT were fused to the GAL4-AD (as
indicated below the panel) and were coexpressed in CV-1 cells together
with either an empty GAL4-DBD or a GAL4-DBD-TFIIB fusion. The ability
of the coexpressed constructs to stimulate expression of a luciferase
reporter bearing GAL4-DBD binding sites, relative to that of a pCH110
reporter lacking GAL4-DBD binding sites (Relative Luc), was measured as
for Fig. 3C.
|
|
Two distinct domains of SMRT bound to TFIIB in vitro. The strongest
binding site mapped to amino acids 96 to 566 of SMRT (Fig. 5A) and was
also be detected in vivo by the mammalian two-hybrid assay
(Fig. 5B). Intriguingly, this strong TFIIB interaction domain encompassed the SMRT SD-1 region, and SMRT truncations that were severely impaired for the TFIIB interaction, such as the
GST-SMRT(214-336) construct, were also severely impaired in
transcriptional repression (compare Fig. 2A and 5A). It therefore
appears that the SD-1 in SMRT strongly interacts with both mSin3A and
TFIIB and that these interactions are both closely linked to the
ability of this domain to repress transcription. A second, weaker TFIIB
association domain was detected in vitro near the extreme C terminus of
SMRT (amino acids 1291 to 1495) (Fig. 5A), but this second TFIIB
interaction domain was apparently too weak for detection by two-hybrid
analysis (Fig. 5B), and this domain of SMRT failed to display any
notable silencing activity when expressed as a GAL4-DBD fusion (Fig.
3B).
Intriguingly, an additional strong interaction also occurred between
TFIIB and the mSin3A component of the corepressor complex (Fig.
6). This interaction could be observed
either with radiolabeled mSin3A and a GST-TFIIB construct (Fig.
6A) or, reciprocally, with radiolabeled TFIIB and a GST-mSin3A
construct (Fig. 6B). The TFIIB interaction domain in mSin3A mapped to
the same PAH3 region, mSin3A amino acids 404 to 545, as conferred
interaction with SMRT (compare Fig. 6A and 3C). Thus, the potential for
an extensive network of multiple interactions between TFIIB, mSin3A,
SMRT, and the nuclear hormone receptors appears to exist. In
contrast to the coincidence of the N-terminal silencing and TFIIB
interaction domains on SMRT itself, however, the TFIIB interaction
domain in mSin3A was neither necessary nor sufficient for
transcriptional silencing by mSin3A GAL4-DBD fusion constructs (compare
Fig. 6 and 3B).

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 6.
TFIIB also interacts with mSin3A. (A) Interaction
between GST-TFIIB and radiolabeled mSin3A. Full-length, radiolabeled
mSin3A was synthesized in vitro by a coupled transcription-translation
protocol. The radiolabeled mSin3A protein was then incubated either
with immobilized nonrecombinant GST or with an immobilized GST-TFIIB
fusion. Radiolabeled mSin3A protein bound to the GST or GST-TFIIB
matrix was eluted with soluble glutathione, resolved by SDS-PAGE, and
visualized and quantified by PhosphorImager analysis. The percentage of
mSin3A bound is depicted numerically below the lanes and was determined
relative to the total radiolabeled mSin3A used in the assay (input).
(B) Localization of domains within mSin3A able to bind to TFIIB.
Radiolabeled TFIIB was synthesized in vitro by a coupled
transcription-translation protocol. The radiolabeled TFIIB protein was
then incubated with various domains of mSin3A (as denoted above the
lanes), each expressed in bacteria as a GST fusion protein and
immobilized on a glutathione-agarose column. Radiolabeled TFIIB bound
to the different GST-mSin3A agarose matrices was eluted with soluble
glutathione, resolved by SDS-PAGE, and visualized and quantified by
PhosphorImager analysis. The binding of TFIIB to nonrecombinant GST
(GST) was also tested in parallel as a negative control. The percentage
of the input TFIIB bound by each GST fusion is also depicted below each
lane.
|
|
We wished to determine if the physical interaction between the
SMRT SD-1 and TFIIB could be manifested as a functional
interaction. We first examined whether TFIIB activity was altered
by SMRT coexpression (Fig. 7A). TFIIB
enhances transcription when tethered to a promoter through a
GAL4 DBD; ectopic expression of SMRT resulted in a modest, but
reproducible and dose-dependent, inhibition of this TFIIB-mediated activation, suggesting that SMRT can indeed counteract TFIIB function (Fig. 7A). Conversely, if SMRT mediates repression by interfering with
TFIIB, one might predict that (i) TFIIB is normally limiting in target
cells and (ii) overexpression of TFIIB might abrogate SMRT-mediated
repression. Consistent with these concepts, elevated expression of TFIIB both enhanced basal promoter expression in CV-1
cells and reversed GAL4-DBD-SMRT-mediated repression in a dose-dependent manner (Fig. 7B). We suggest that TFIIB
is potentially a target through which SMRT may mediate
at least certain facets of transcriptional repression (see
Discussion).

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 7.
SMRT and TFIIB interact functionally. (A) SMRT
expression inhibits transcriptional activation by TFIIB. A GAL4-DBD or
GAL4-DBD-TFIIB construct (125 ng per plate) was introduced
into CV-1 cells alone or with increasing amounts of a pSG5-SMRT
derivative (1× = 125 ng/plate). The activity of the cointroduced
GAL4 17-mer-luciferase (LUC) reporter was determined relative to that
of the pCH110 lacZ internal control as for Fig. 2 and 3. (B)
TFIIB expression counteracts SMRT-mediated repression. A GAL4-DBD or
GAL4-DBD-SMRT fusion construct (125 ng per plate) was expressed in
CV-1 cells alone or together with TFIIB (1× = 125 ng/plate). The
activity of the cointroduced GAL4 (17-mer)-luciferase reporter was then
determined relative to that of the pCH110 lacZ internal
control as for Fig. 2 and 3.
|
|
N-CoR shares the ability of SMRT to interact with mSin3A and with
TFIIB.
N-CoR is a second corepressor protein that is approximately
50% related to SMRT over regions of overlap but that also displays unique N-terminal sequences not present in SMRT. We therefore wished to
extend our studies to an analysis of N-CoR. Although the silencing
domains of N-CoR are divergent from those of SMRT, N-CoR shared the
ability of SMRT to interact with mSin3A (Fig. 8A). N-CoR interacted primarily with the
N terminus and PAH3 domains of mSin3A under our conditions and did not
appear to interact detectably with the PAH2 domain (Fig. 8A). Notably,
N-CoR also shared the ability of SMRT to bind to TFIIB (Fig. 8B), thus
extending this observation to a second member of the corepressor
family.

View larger version (30K):
[in this window]
[in a new window]
|
FIG. 8.
Interactions of N-CoR with mSin3A and TFIIB. (A)
Interaction between N-CoR and mSin3A. Radiolabeled N-CoR, synthesized
by in vitro transcription and translation, was tested for the
ability to bind to GST fusions representing various domains of
mSin3A or to nonrecombinant GST, as indicated above the lanes.
Radiolabeled N-CoR bound to each GST construct was eluted with soluble
glutathione, resolved by SDS-PAGE, and visualized and quantified by
PhosphorImager analysis. The percentage of N-CoR bound in each assay is
depicted below the lanes, and was determined relative to the total
radiolabeled N-CoR used in the assay (input). (B) Interaction between
N-CoR and TFIIB. The same protocol as in panel A was employed, but with
a GST-TFIIB construct.
|
|
 |
DISCUSSION |
SMRT associates with an assortment of polypeptides that
appear to participate in corepressor-mediated transcriptional
silencing.
Efficient transcriptional silencing by nuclear hormone
receptors in vivo appears to be predicated on the ability of these transcription factors to physically interact with the SMRT/N-CoR corepressor proteins (10, 11, 24, 26, 29, 31, 39, 42-44, 54-56,
58). The recognition that the SMRT/N-CoR proteins are part of
a larger complex that includes mSin3A or -B, HDAC-1 or -2, RbAP46
or -48, and a panel of as-yet-uncharacterized other polypeptides establishes an important conceptual context with which to understand this mode of transcriptional silencing (1, 3,
21, 22, 30, 31, 59). Significantly, the SMRT-mSin3A-HDAC-1 complex also appears to be an important mediator of transcriptional silencing by a wide variety of nonreceptor transcription factors in
vertebrates, and orthologs of Sin3 and HDAC have been implicated in
transcriptional repression in yeast (13, 19, 28, 31-34, 36, 38,
45-48). Therefore, components of the SMRT-Sin3-HDAC corepressor
complex appear to represent ancestral, and widely exploited, molecular
effectors by which eukaryotes negatively regulate gene expression.
The presence of HDAC in the corepressor complex is particularly
provocative and has led to the proposal that transcriptional repression may be, in part, mediated through the covalent
modification of the chromatin template (see, e.g., references
37 and 51). We wished to better
elucidate the manner in which the different components of the
corepressor complex interact with one another and to establish which of
these interactions are key to the transcriptional silencing phenotype.
In the work presented here, we have confirmed that SMRT can
interact with mSin3, which can interact, in turn, with HDAC-1.
However, our detailed mapping of the determinants involved in
these interactions indicates that transcriptional silencing is
actually a multifaceted phenomenon, with both SMRT and mSin3 able
to exhibit significant transcriptional repression in the absence of
detectable association with each other and in the absence of detectable
interaction with HDAC-1. Our work further suggests that one of
these multiple modes of SMRT-mediated repression may operate through
targeting of TFIIB. This observation appears to reconcile the actions
of the corepressors with prior work implicating the transcriptional
preinitiation complex itself as a target for nuclear hormone
receptor-mediated gene regulation (5, 17, 18).
SMRT possess two transcriptional silencing domains, one of which
confers interaction with mSin3A and the other of which mediates
silencing by an as-yet-unelucidated mechanism.
Both silencing
domains in SMRT are located within the N terminus and are physically
and functionally distinct from the more C-terminal SMRT domains
that confer interaction with the T3R, retinoic acid receptor, and
retinoid X receptor (RXR) nuclear hormone receptors (summarized in Fig.
9). Although these silencing domains were
mapped in our experiments by their ability, as GAL4-DBD fusions, to
repress reporter gene transcription, the same SD-1 and SD-2 also appear
to be critical for repression mediated by full-length SMRT. In fact,
deletion of the SD-1 and SD-2 of SMRT converts the native protein from
a corepressor into a dominant negative inhibitor of repression
(10, 11, 39).

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 9.
Summary of the interactions elucidated by the
corepressor complex. Schematic representations of mSin3A (top) and SMRT
(bottom) are shown. Arrows indicate the domains of each protein that
mediate observable interactions with the domains of the other
and/or with TFIIB. Also depicted are the locations of the domains
of these proteins that can mediate transcriptional repression when
expressed as GAL4-DBD fusions (SD-A and -B in mSin3A and SD-1 and -2 in
SMRT). Numbers above or below each schematic refer to the relevant
amino acid positions.
|
|
In our hands, the same SD-1 region of SMRT was also the site of
interaction with mSin3A (summarized in Fig. 9); this SMRT-mSin3A interaction was detectable both by a protein-protein binding assay in
vitro and by a mammalian two-hybrid characterization in vivo. Deletions
that severely impaired the ability of SD-1 to bind to mSin3A also
severely impaired the ability of SD-1 to repress, consistent with a correlation between mSin3A recruitment to SD-1 and transcriptional repression by this SMRT subdomain.
In contrast to this strong SD-1-mSin3A interaction, however, we were
unable to observe a significant interaction between the SD-2 region of
SMRT and mSin3A or, in fact, between SD-2 and any of the other
corepressor proteins tested here. Some prior reports have suggested
that both SD-1 and SD-2 can interact with mSin3 (24, 31).
Notably, however, these reported interactions between mSin3 and SD-2
were much weaker than those observed with SD-1 and were detected only
by two-hybrid analysis or by low-stringency immunoprecipitation of cell
extracts; the interaction between SD-2 and mSin3 may, therefore, be an
indirect one and appears to be disproportionally weak compared to the
strong silencing phenotype of SD-2. Conversely, it might be argued that
our own failure to observe an interaction between SD-2 and mSin3A by
mammalian two-hybrid analysis may also reflect a technical limitation:
strong silencing domains, such as SD-2, can be difficult to
analyze by the two-hybrid approach, given that the repression domain
can overwhelm the function of a tethered AD fusion. Significantly, however, we also observed no evidence for an SD-2-mSin3A
interaction in vitro, using a protein-protein binding assay
that is not subject to the limitations of the two-hybrid methodology.
Our results are therefore most consistent with SMRT SD-2 mediating
transcriptional silencing by a mechanism distinct from a strong, direct
recruitment of mSin3A.
Transcriptional repression by mSin3A does not require a detectable
interaction with either SMRT or HDAC-1.
At least two distinct
domains of mSin3 are able to mediate transcriptional repression
when expressed as GAL4-DBD fusion polypeptides: SD-A
(located at the mSin3A N terminus and overlapping the PAH1 region) and SD-B (located between the PAH3 and PAH4 domains of mSin3A) (Fig. 9). Intriguingly, neither of these silencing domains in
mSin3 coincides with the domains that interact with SMRT; the SMRT interaction domains map instead to regions of mSin3A encompassing the PAH2 and PAH3 domains (Fig. 9). Our results are consistent with prior reports that N-terminal truncations of mSin3 are impaired in
repression (1, 22), but our detailed dissection suggests that it is the loss of the N-terminal SD-A region, rather than loss of
the adjacent SMRT interaction domain, that is primarily responsible for
this impairment. Notably, although unable to recruit SMRT, the
N-terminal SD-A region of mSin3A is able to recruit a related
corepressor protein, N-CoR (Fig. 8A) (1, 22). It is
therefore possible that an interaction with N-CoR, and not SMRT, is
necessary for mSin3A-mediated transcriptional repression. Alternatively, other, yet-to-be identified factors may interact with
the mSin3A N terminus to mediate repression. Furthermore, SMRT itself
appears likely to contribute to at least some aspects of gene silencing
by the native corepressor complex through the actions of the SMRT SD-2
domain and/or through the ability of SMRT to interact with the
general transcriptional machinery (see below).
In addition to interacting with SMRT and N-CoR, mSin3A was also able to
bind to HDAC-1 in vitro; in agreement with prevailing models, the
HDAC-1 interaction site included the SD-B region of mSin3A (1,
30). In contrast, HDAC-1 does not appear to interact directly
with SMRT. The ability of mSin3A to recruit HDAC-1 through its SD-B
may, as proposed elsewhere, be an important facet of mSin3A-mediated
transcriptional silencing (37, 51). Our own results,
however, indicate that HDAC-1 recruitment is not the only mechanism
through which mSin3A mediates repression. Most provocative is
the presence of the second strong silencing domain within
mSin3A, SD-A, that fails to detectably recruit HDAC in vitro (our data)
or in vivo (30) and thus appears to function in a HDAC-1
and -2-independent manner. Further suggestive is our observation that
trichostatin A, a potent inhibitor of HDAC, has no detectable effect on
transcriptional repression in any of our transient-transfection assays.
Our results are consistent with previous reports demonstrating that
inhibition of the ability of Sin3 to interact with HDAC-1 and -2, or inhibition of the activity of the deacetylase itself,
often results in only a partial reversal of repression
(3, 21, 22, 28, 30). In fact, different promoters appear to
be subject to different mechanisms of repression; for example, the SV40
late promoter utilized in our own experiments has been reported to be
refractory to the antirepression effects of trichostatin A
(33). This work, taken as a whole, strongly indicates that
corepressor-mediated transcriptional silencing is a multifaceted
phenomenon and that different components of the corepressor complex
contribute to different aspects of repression.
TFIIB represents a potential target for SMRT-mediated
transcriptional repression.
What other mechanisms might
participate in SMRT-mediated transcriptional repression? A
substantial body of evidence indicates that nuclear hormone
receptors can interfere with the formation of a transcriptional
preinitiation complex in vitro, apparently through direct
inhibitory contacts of receptor with components of the general
transcriptional machinery (5, 17, 18). This form of
autonomous repression in vitro, mediated by direct interactions between
receptor and the preinitiation complex, has previously been difficult
to reconcile with the apparent obligatory requirement for the
corepressor complex for gene silencing in vivo. However, in this
paper we report that the SMRT polypeptide is itself also capable of interaction with TFIIB; in fact, this TFIIB interaction is
equal to or greater in magnitude than the extremely strong interaction
observed between SMRT and the nuclear hormone receptors.
Significantly, the ability of SMRT to interact with TFIIB
correlates closely with SMRT-mediated repression. For example, the determinants that define SD-1 within SMRT overlap with the determinants that confer the TFIIB interaction (Fig. 9). Similarly,
overexpression of TFIIB can overcome at least some elements of
SMRT-mediated repression. Intriguingly, TFIIB also demonstrates a
specific and equally strong interaction with mSin3A; in this context,
however, the TFIIB interaction maps to a separate site on mSin3A
distinct from the mSin3A domains that confer repression. We propose
that, in addition to possible modification of the chromatin template, transcriptional silencing by nuclear hormone receptors involves a
network of concordant physical interactions between the nuclear hormone
receptor, the corepressor complex, and the general transcriptional machinery that may interfere with formation of a functional
preinitiation complex. Although our own data clearly implicate
TFIIB as one plausible target through which repression may be mediated,
it is important to note that neither the TFIIB interactions elucidated here nor interaction with HDAC-1 and -2 appears likely to account for all of the silencing properties of SMRT and mSin3A; presumably still more mechanisms remain to be elucidated.
When this paper was under review, we learned of work by others (G. E. O. Muscat, L. J. Burke, and M. Downes) reporting that, in
common with SMRT, the N-CoR corepressor also interacts physically with
TFIIB (35a), an observation that we have confirmed in our own work. Muscat et al. further report that N-CoR can inhibit the
ability of TFIIB to recruit the TAFII-32 subunit of TFIID, an interaction important for transcriptional activation in
certain promoter contexts. Thus, SMRT and N-CoR both have the
potential to exert profound effects on the function of the general
transcriptional machinery.
A recurring theme: multiple interactions through multiple, often
overlapping, sites.
One outcome of these studies is the finding of
an unanticipated multiplicity of interactions that can occur between
different components of the transcriptional repression machinery (Fig.
9). A single domain within SMRT, for example, can interact both with mSin3A and with TFIIB. Conversely, one of the mSin3A domains that binds
SMRT also binds TFIIB. This concept of multiple interactions extends to
the contacts between the corepressor complex and the DNA-binding
transcription factors that tether it. For example, T3Rs recruit
corepressor by interacting with two different sites in the C terminus
of SMRT (11, 39, 42, 54), whereas recruitment of corepressor
by PLZF is mediated by multiple contacts between PLZF, the N and C
termini of SMRT, and mSin3 (19, 23, 32, 51a). It is tempting
to speculate that this multiplicity of interactions might generate both
synergistic and antagonistic outcomes and thus might serve regulatory
roles. For example, the interactions of TFIIB and mSin3A with the SD-1
of SMRT may be mutually exclusive and thus indicative of the existence
of two alternative forms of SMRT complex, and two distinct modes of
SMRT function, in the cell. Alternatively, certain of the interactions
between different components of the corepressor machinery may occur
simultaneously and be mutually enhancing or may occur sequentially in a
temporally ordered fashion that leads to the step-by-step assembly of a
functional corepressor complex on a target promoter. Future work will
need to focus on these questions.
We are indebted to D. Ayer, R. N. Eisenman, C. A. Hassig, M. A. Lazar, M. G. Rosenfeld, and S. L. Schreiber for generously providing molecular clones. We also thank
Shelly Meeuson and Linfong Tzeng, who, as rotation students, assisted
with some of the recombinant constructs, and Valentina Taryanik for
technical help.
This work was supported by Public Health Service grant CA53394 from the
National Cancer Institute.
| 1.
|
Alland, L.,
R. Muhle,
H. Hou,
J. Potes,
L. Chin,
N. Schreiber-Agus, and R. A. DePinho.
1997.
Role of N-CoR and histone deacetylase in Sin3-mediated transcriptional repression.
Nature
387:49-55[Medline].
|
| 2.
|
Ayer, D. E.,
L. Kretzner, and R. N. Eisenman.
1993.
Mad: a heterodimeric partner for Max that antagonizes Myc transcriptional activity.
Cell
72:211-222[Medline].
|
| 3.
|
Bagy, L.,
H.-Y. Kao,
D. Chakravarti,
R. J. Lin,
C. A. Hassig,
D. E. Ayer,
S. L. Schreiber, and R. M. Evans.
1997.
Nuclear receptor repression mediated by a complex containing SMRT, mSin3A and histone deacetylase.
Cell
89:373-380[Medline].
|
| 4.
|
Baniahmad, A.,
A. C. Kohne, and R. Renkawitz.
1992.
A transferable silencing domain is present in the thyroid hormone receptor, in the v-Erb A oncogene product, and in the retinoic acid receptor.
EMBO J.
11:1015-1023[Medline].
|
| 5.
|
Baniahmad, A.,
I. Ha,
D. Reinberg,
S. Y. Tsai,
M.-J. Tsai, and B. W. O'Malley.
1993.
Interaction of human thyroid hormone receptor beta with transcription factor TFIIB may mediate target gene derepression and activation by thyroid hormone.
Proc. Natl. Acad. Sci. USA
90:8832-8836[Abstract/Free Full Text].
|
| 6.
|
Baniahmad, A.,
X. Leng,
T. P. Burris,
S. Y. Tsai,
M. J. Tsai, and B. W. O'Malley.
1995.
The 4 activation domain of the thyroid hormone receptor is required for release of a putative corepressor(s) necessary for transcriptional silencing.
Mol. Cell. Biol.
15:76-86[Abstract].
|
| 7.
|
Casanova, J.,
E. Helmer,
S. Selmi-Ruby,
J. S. Qi,
M. Au-Flieger,
V. Desai-Yajnik,
N. Koudinova,
F. Yarm,
B. M. Raaka, and H. H. Samuels.
1994.
Functional evidence for ligand-dependent dissociation of thyroid hormone and retinoid acid receptors from an inhibitory cellular factor.
Mol. Cell. Biol.
14:5756-5765[Abstract/Free Full Text].
|
| 8.
|
Chen, H.-W., and M. L. Privalsky.
1993.
The erbA oncogene represses the actions of both retinoid X and retinoid A receptors but does so by distinct mechanisms.
Mol. Cell. Biol.
13:5970-5980[Abstract/Free Full Text].
|
| 9.
|
Chen, H.-W., and M. L. Privalsky.
1997.
Retinoid X and retinoic acid receptors interact with TFIIB by distinct mechanisms.
Mol. Cell. Endocrinol.
129:55-61[Medline].
|
| 10.
|
Chen, J. D., and R. M. Evans.
1995.
A transcriptional co-repressor that interacts with nuclear hormone receptors.
Nature
377:454-457[Medline].
|
| 11.
|
Chen, J. D.,
K. Umesono, and R. M. Evans.
1996.
SMRT isoforms mediate repression and anti-repression of nuclear receptor heterodimers.
Proc. Natl. Acad. Sci. USA
93:7567-7571[Abstract/Free Full Text].
|
| 12.
|
Damm, K.,
C. C. Thompson, and R. M. Evans.
1989.
Protein encoded by v-Erb A functions as a thyroid hormone receptor antagonist.
Nature
339:593-597[Medline].
|
| 13.
|
DeRurbertis, F.,
D. Kadosh,
S. Henchoz,
D. Pauli,
G. Reuter,
K. Struhl, and P. Spierer.
1991.
The histone deacetylase RPD3 counteracts genomic silencing in Drosophila and yeast.
Nature
384:589-591.
|
| 14.
|
Dhordain, P.,
O. Albagli,
R. J. Lin,
S. Ansieau,
S. Quief,
A. Leutz,
J. P. Kerckaert,
R. M. Evans, and D. Leprince.
1997.
Corepressor SMRT binds the BTB/POZ repressing domain of the LAZ3/BCL-6 oncoprotein.
Proc. Natl. Acad. Sci. USA
94:10762-10767[Abstract/Free Full Text].
|
| 15.
|
Downes, M.,
L. J. Burke,
P. J. Bailey, and G. E. Muscat.
1996.
Two receptor interaction domains in the corepressor, N-CoR/RIP13, are required for an efficient interaction with Rev-erbA alpha and RVR: physical association is dependent on the E region of the orphan receptors.
Nucleic Acids Res.
2:4379-4386.
|
| 16.
|
Felsenfeld, G.
1996.
Chromatin unfolds.
Cell
86:13-19[Medline].
|
| 17.
|
Fondell, J. D.,
A. L. Roy, and R. G. Roeder.
1993.
Unliganded thyroid hormone receptor inhibits formation of a functional preinitiation complex: implications for active repression.
Genes Dev.
7:1400-1410[Abstract/Free Full Text].
|
| 18.
|
Fondell, J. D.,
F. Brunel,
K. Hisatake, and R. G. Roeder.
1996.
Unliganded thyroid hormone receptor a can target TATA-binding protein for transcriptional repression.
Mol. Cell. Biol.
16:281-287[Abstract].
|
| 19.
|
Grignani, F.,
S. De Matteis,
C. Nervi,
L. Tomassoni,
V. Gelmetti,
M. Cioce,
M. Fanelli,
M. Ruthardt,
F. F. Ferrara,
I. Zamir,
C. Seiser,
F. Grignani,
M. A. Lazar,
S. Minucci, and P. G. Pelicci.
1998.
Fusion proteins of the retinoic acid receptor- recruit histone deacetylase in promyelocytic leukemia.
Nature
391:815-818[Medline].
|
| 20.
|
Guan, K. L., and J. E. Dixon.
1991.
Eukaryotic proteins expressed in Escherichia coli: an improved thrombin cleavage and purification procedure of fusion proteins with glutathione S-transferase.
Anal. Biochem.
192:262-267[Medline].
|
| 21.
|
Hassig, C. A.,
T. C. Fleischer,
A. N. Billin,
S. L. Schreiber, and D. E. Ayer.
1997.
Histone deacetylase activity is required for full transcriptional repression by mSin3A.
Cell
89:341-347[Medline].
|
| 22.
|
Heinzel, T.,
R. M. Lavinsky,
T.-M. Mullen,
M. Soderstrom,
C. D. Laherty,
J. Torchia,
W.-M. Yang,
G. Brard,
S. G. Ngo,
J. R. Davie,
E. Seto,
R. N. Eisenman,
D. W. Rose,
C. K. Glass, and M. G. Rosenfeld.
1997.
A complex containing N-CoR, mSin3, and histone deacetylase mediates transcriptional repression.
Nature
387:43-48[Medline].
|
| 23.
|
Hong, S.-H.,
G. David,
C. W. Wong,
A. Dejean, and M. L. Privalsky.
1997.
SMRT corepressor interacts with PLZF, and with the PML-RAR and PLZF-RAR oncoproteins associated with acute promyelocytic leukemia.
Proc. Natl. Acad. Sci. USA
94:9028-9033[Abstract/Free Full Text].
|
| 24.
|
Horlein, A. J.,
A. M. Naar,
T. Heinzel,
J. Torchia,
B. Gloss,
R. Kurokawa,
A. Ryan,
Y. Kamel,
M. Soderstrom,
C. K. Glass, and M. G. Rosenfeld.
1995.
Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor.
Nature
377:397-404[Medline].
|
| 25.
|
Horwitz, K. B.,
T. A. Jackson,
D. L. Bain,
J. K. Richer,
G. S. Takimoto, and L. Tung.
1996.
Nuclear hormone receptor coactivators and corepressors.
Mol. Endocrinol.
10:1167-1177[Abstract].
|
| 26.
|
Jackson, T. A.,
J. K. Richer,
D. L. Bain,
G. S. Takimoto,
L. Tung, and K. B. Horwitz.
1997.
The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT.
Mol. Endocrinol.
11:693-705[Abstract/Free Full Text].
|
| 27.
|
Johnston, L. A.,
S. J. Tapscott, and H. Eisen.
1992.
Sodium butyrate inhibits myogenesis by interfering with transcriptional activation functions of MyoD and myogenin.
Mol. Cell. Biol.
12:5123-5130[Abstract/Free Full Text].
|
| 28.
|
Kadosh, D., and K. Struhl.
1997.
Repression by Ume6 involves recruitment of a complex containing Sin3 corepressor and Rpd3 histone deacetylase to target promoters.
Cell
89:365-371[Medline].
|
| 29.
|
Kurokawa, R.,
M. Soderstrom,
A. Horlein,
S. Halachmi,
M. Brown,
M. G. Rosenfeld, and C. K. Glass.
1995.
Polarity-specific activities of retinoic acid receptors determined by a co-repressor.
Nature
377:451-454[Medline].
|
| 30.
|
Laherty, C. D.,
W.-M. Yang,
J.-M. Sun,
J. R. Davie,
E. Seto, and R. N. Eisenman.
1997.
Histone deacetylases associated with the mSin3A corepressor mediate Mad transcriptional repression.
Cell
89:349-356[Medline].
|
| 31.
|
Li, H.,
C. Leo,
D. J. Schroen, and J. D. Chen.
1997.
Characterization of receptor interaction and transcriptional repression by the corepressor SMRT.
Mol. Endocrinol.
11:2025-2037[Abstract/Free Full Text].
|
| 32.
|
Lin, R. J.,
L. Nagy,
S. Inoue,
W. Shao,
W. H. Miller, Jr., and R. M. Evans.
1998.
Role of the histone deacetylase complex in acute promyelocytic leukemia.
Nature
391:811-814[Medline].
|
| 33.
|
Luo, R. X.,
A. A. Postigo, and D. C. Dean.
1998.
Rb interacts with histone deacetylase to repress transcription.
Cell
92:463-473[Medline].
|
| 34.
|
McKenzie, E. A.,
N. A. Kent,
S. J. Dowell,
F. Moreno,
L. E. Bird, and J. Mellor.
1993.
The centromere and promoter factor 1, CPF1, of Saccharomyces cerevisiae modulates gene activity through a family of factors, including SPT21, RPD1(DIN3), RPD3, and CCR4.
Mol. Gen. Genet.
240:374-386[Medline].
|
| 35.
|
McKnight, G. S.,
L. Hager, and R. D. Palmiter.
1980.
Butyrate and related inhibitors of histone deacetylase block the induction of egg white genes by steroid hormones.
Cell
22:469-477[Medline].
|
| 35a.
|
Muscat, G. E. O.,
L. J. Burke, and M. Downes.
1998.
The corepressor N-CoR and its variants RIP13a and RIP 1 directly interact with the basal transcription factors TFIIB, TAFII32, and TAFII70.
Nucleic Acids Res.
26:2899-2907[Abstract/Free Full Text].
|
| 36.
|
Nasmyth, K.,
D. Stillman, and D. Kipling.
1987.
Both positive and negative regulators of HO transcription are required for mother-cell-specific mating type switching in yeast.
Cell
48:579-589[Medline].
|
| 37.
|
Pazin, M. J., and J. T. Kadonaga.
1997.
What's up and down with histone deacetylation and transcription?
Cell
89:325-328[Medline].
|
| 38.
|
Rundlett, S. E.,
A. A. Carmen,
R. Kobayashi,
S. Bavykin,
B. M. Turner, and M. Grunstein.
1996.
HDA1 and RPD3 are members of distinct yeast histone deacetylase complexes that regulate silencing and transcription.
Proc. Natl. Acad. Sci. USA
93:14503-14508[Abstract/Free Full Text].
|
| 39.
|
Sande, S., and M. L. Privalsky.
1996.
Identification of TRACs (T3 receptor-associating cofactors) a family of cofactors that associate with, and modulate the activity of, nuclear hormone receptors.
Mol. Endocrinol.
10:813-825[Abstract].
|
| 40.
|
Sap, J.,
A. Munoz,
H. Schmitt,
H. Stunnenberg, and B. Vennstrom.
1989.
Repression of transcription mediated by a thyroid hormone response element by the v-Erb A oncogene product.
Nature
340:242-244[Medline].
|
| 41.
|
Schreiber-Agus, N.,
L. Chin,
K. Chen,
R. Torres,
G. Rao,
P. Guida,
A. I. Skoultichi, and R. A. DePinho.
1995.
An amino-terminal domain of Mxi1 mediates anti-Myc oncogenic activity and interacts with a homolog of the yeast transcriptional repressor SIN3.
Cell
80:777-786[Medline].
|
| 42.
|
Seol, W.,
M. J. Mahon,
Y. K. Lee, and D. D. Moore.
1996.
Two receptor interacting domains in the nuclear hormone receptor corepressor RIP13/N-CoR.
Mol. Endocrinol.
10:1646-1655[Abstract].
|
| 43.
|
Shibata, H.,
Z. Nawaz,
S. Y. Tsai, and B. W. O'Malley.
1997.
Gene silencing by COUP-TF is mediated by transcriptional corepressors, N-CoR and SMRT.
Mol. Endocrinol.
11:714-724[Abstract/Free Full Text].
|
| 44.
|
Smith, C. L.,
Z. Nawaz, and B. W. O'Malley.
1997.
Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogn, 4-hydroxytamoxifen.
Mol. Endocrinol.
11:657-666[Abstract/Free Full Text].
|
| 45.
|
Sternberg, P. W.,
M. J. Stern,
I. Clark, and I. Herskowitz.
1987.
Activation of the yeast HO gene by release from multiple positive and negative controls.
Cell
48:567-577[Medline].
|
| 46.
|
Stillman, D. J.,
S. Dorland, and Y. Yu.
1994.
Epistasis analysis of suppressor mutations that allow HO expression in the absence of the yeast SWI5 transcriptional activator.
Genetics
136:781-788[Abstract].
|
| 47.
|
Sussel, L.,
D. Vannier, and D. Shore.
1995.
Suppressors of defective silencing in yeast: effects on transcriptional repression at the HMR locus, cell growth, and telomere structure.
Genetics
141:873-888[Abstract].
|
| 48.
|
Vidal, M., and R. F. Gaber.
1991.
RPD3 encodes a second factor required to achieve maximum positive and negative transcriptional states in Saccharomyces cerevisiae.
Mol. Cell. Biol.
11:6317-6327[Abstract/Free Full Text].
|
| 49.
|
Wade, P. A.,
D. Pruss, and A. P. Wolffe.
1997.
Histone acetylation: chromatin in action.
Trends Biochem. Sci.
22:128-132[Medline].
|
| 50.
|
Wang, H., and D. J. Stillman.
1993.
Transcriptional repression in Saccharomyces cerevisiae by a SIN3-LexA fusion protein.
Mol. Cell. Biol.
13:1805-1814[Abstract/Free Full Text].
|
| 51.
|
Wolffe, A. P.
1997.
Sinful repression.
Nature
387:16-17[Medline].
|
| 51a.
| Wong, C.-W., and M. L. Privalsky.
Submitted for publication.
|
| 52.
|
Yang, W.-M.,
C. Inouye,
Y. Zeng,
D. Bearss, and E. Seto.
1996.
Transcriptional repression by YY1 is mediated by interaction with a mammalian homolog of the yeast global regulatory RPD3.
Proc. Natl. Acad. Sci. USA
93:12845-12850[Abstract/Free Full Text].
|
| 53.
|
Yoshida, M.,
S. Horinouchi, and T. Beppu.
1995.
Trichostatin A and trapoxin: novel chemical probes for the role of histone deacetylation in chromatin structure and function.
Bioessays
17:423-430[Medline].
|
| 54.
|
Zamir, I.,
H. P. Harding,
G. B. Atkins,
A. Horlein,
C. K. Glass,
M. Rosenfeld, and M. A. Lazar.
1996.
A nuclear hormone receptor corepressor mediates transcriptional silencing by receptors with distinct repression domains.
Mol. Cell. Biol.
16:5458-5465[Abstract].
|
| 55.
|
Zamir, I.,
J. Dawson,
R. M. Lavinsky,
C. K. Glass,
M. G. Rosenfeld, and M. A. Lazar.
1997.
Cloning and characterization of a corepressor and potential component of the nuclear hormone receptor repression complex.
Proc. Natl. Acad. Sci. USA
94:14400-14411[Abstract/Free Full Text].
|
| 56.
|
Zamir, I.,
J. Zhang, and M. A. Lazar.
1997.
Stoichiometric and steric principles governing repression by nuclear hormone receptors.
Genes Dev.
11:835-846[Abstract/Free Full Text].
|
| 57.
|
Zervos, A. S.,
J. Gyuris, and R. Brent.
1993.
Mxi 1, a protein that specifically interacts with Max to bind Myc-Max recognition sites.
Cell
72:223-232[Medline].
|
| 58.
|
Zhang, J.,
I. Zamir, and M. A. Lazar.
1997.
Differential recognition of liganded and unliganded thyroid hormone receptor by retinoid X receptor-regulated transcriptional repression.
Mol. Cell. Biol.
17:6887-6897[Abstract].
|
| 59.
|
Zhang, Y.,
R. Iratni,
H. Erdjument-Bromage,
P. Tempst, and D. Reinberg.
1997.
Histone deacetylases and SAP18 a novel polypeptide, are components of a human Sin3 complex.
Cell
89:357-364[Medline].
|